SYNGENE · Syngene International Ltd · Biotechnology & Drugs
SYNGENE · Syngene International Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
39.0% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹736 Cr
Revenue YoY
PAT YoY
-110.4%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
3.2
P/S (TTM)
4.3
Sector P/E
42
Dividend yield
+0.3%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| SYNGENE (this stock) | 80 | 3.2 | +6.1% | +4.6% | 0.09 | +0.3% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
falling 1q
FII
falling 3q
MF
25.78% (+1.60pp)
rising 3q
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| date | canonicalSymbol | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| 2026-05-01 | SYNGENE | 4926886 | 2 | WEAK | BULK |
| 2026-04-30 | SYNGENE | 4926886 | 2 | WEAK | BULK |
News timeline
- mediummacroeconomictimes.indiatimes.com· 28 Oct 2026, 09:08 pmAhead of Market: 10 things that will decide stock market action on Wednesday
- loweconomictimes.indiatimes.com· 12 Oct 2026, 08:53 pmAhead of Market: 10 things that will decide stock market action on Tuesday
- unknowneconomictimes.indiatimes.com· 28 Sept 2026, 01:21 pmFIIs cut stake in 12 smallcap stocks over 2 quarters; shares fall up to 50% in CY26 - Portfolio Tracker
- loweconomictimes.indiatimes.com· 22 Sept 2026, 09:37 amSyngene International among 4 stocks that closed crossing above VWAP - Stocks Gain Momentum
Concalls & investor presentations
AI-generatedKey takeaway: Syngene International Limited provided an intimation regarding the earnings conference call transcript for Q1 FY2027, which was held on July 30, 2026. The document included a web link to access the transcript on the company's website. The communication was directed to the BSE Limited and the National Stock Exchange of India Limited, ensuring compliance with SEBI regulations. The Company Secretary and Compliance Officer, Chethan Yogesh, signed the document, affirming its authenticity.
The document presented factual information regarding the earnings call without emphasizing growth or challenges.
Sourced from an exchange-filed transcript, dated 06 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The investor presentation for Syngene International Limited for the quarter ended June 30, 2026, reported a revenue from operations of Rs 736 crore, reflecting a 16% year-over-year decline. The operating EBITDA margin was noted at 12%, down from 24% in the same quarter last year. The presentation highlighted the appointment of Siddharth Mittal as Managing Director & CEO and the signing of a Memorandum of Understanding with BRIC-Translational Health Science and Technology Institute for clinical development collaboration. Syngene's AI-enabled platform, Syn.AI, was further enhanced to improve drug discovery services. The company was recognized in TIME Magazine's
The presentation included both positive developments and challenges faced by the company.
Sourced from an exchange-filed presentation, dated 29 Jul 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Syngene International Limited provided an intimation regarding the earnings call transcript for Q4 FY2026, which was held on April 30, 2026. The company communicated this information to the BSE Limited and the National Stock Exchange of India Limited, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. A web link to the transcript was included in the communication, directing stakeholders to the company's website for access. The document was signed by Chethan Yogesh, the Company Secretary & Compliance Officer, and included the company's contact details and corporate information.
The document presented factual information regarding the earnings call without emphasizing any particular sentiment.
Sourced from an exchange-filed transcript, dated 04 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The investor presentation for Syngene International Limited for the quarter and year ended March 31, 2026, reported a revenue from operations of Rs 1,037 crore, reflecting a 2% year-on-year increase, while the operating EBITDA margin decreased to 29% from 34% in the previous year. The presentation highlighted the commencement of operations at the ADC discovery laboratory and the completion of 14 audits during the quarter, reinforcing quality standards. Management noted key leadership changes, including Kiran Mazumdar-Shaw transitioning to Executive Chairperson and Siddharth Mittal appointed as Managing Director & CEO. For FY26, revenue from operations was Rs 3,739 crore, a 3% increase year-on-year, with a PAT before exceptional items of Rs 380 crore, down 20% from FY25. The document emphasized Syngene's commitment to sustainability, achieving recognition in the S&P Global Sustainability Yearbook 2026.
The presentation provided a balanced overview of financial performance and strategic initiatives without strong emphasis on growth or challenges.
Sourced from an exchange-filed presentation, dated 30 Apr 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedSyngene International Limited reported a 34.9% decrease in standalone Profit After Tax (PAT) to ₹3,049 Mn in FY2025-26, with EBITDA down 10.8% to ₹8,815 Mn. The company faced a fine of ₹20,000 from BSE and NSE for non-compliance with Nomination and Remuneration Committee regulations. No defaults in loan repayments or regulatory actions under the Insolvency and Bankruptcy Code were noted. Contingent liabilities include unresolved tax disputes and potential impacts from the Supreme Court's definition of 'Basic Wages'.
- Profit After Tax decreased by 34.9% to ₹3,049 Mn on standalone basis and 36.2% to ₹3,167 Mn on consolidated basis.
- Received a fine of ₹20,000 from BSE and NSE for deviations in Nomination and Remuneration Committee composition.
- Contingent liabilities include unresolved income tax disputes for FY2008-09 to FY2021-22 and indirect tax disputes for FY2009-10 to FY2017-18.
- No defaults in loan repayments or regulatory actions under the Insolvency and Bankruptcy Code.
- The Supreme Court's definition of 'Basic Wages' creates uncertainty in provident fund obligations, classified as a contingent liability.
Key takeaway: Syngene International Limited faces significant declines in profitability and regulatory fines, alongside unresolved tax disputes and legal uncertainties, which could affect its financial stability.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (1 item); Default / Covenant Breach (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
1 occurrenceRecent (last 12 months)
BSE Limited and National Stock Exchange of India Limited imposed a fine of ₹20,000 (excluding GST) on Syngene International Limited for deviations in the composition of the Nomination and Remuneration Committee under SEBI LODR Regulations, 2015 during July 22nd to 31st, 2025. The company paid the fine to both exchanges.
Default / Covenant Breach
1 occurrenceEarlier (1-3 years ago)
The company has statutory dues in arrears for Income Tax under the Income Tax Act, 1961, with disputes pending before the Commissioner of Income Tax Appeals for the periods 2011-12 to 2018-19 and 2020-21 to 2021-22.
Routine disclosures
Contingent Liability
3 occurrencesRecent (last 12 months)
The company has contingent liabilities related to income tax disputes for financial years 2008-09, 2012-13 to 2018-19, 2020-21, and 2021-22, and indirect tax disputes for financial years 2009-10 to 2017-18.
Earlier (1-3 years ago)
During the quarter ended 31 March 2025, the Company opted for Vivad se Vishwas Scheme, 2024, resulting in the settlement of pending TDS assessments related to non-resident tax deductions. This led to a reduction of contingent liabilities by Rs 197 million.
Contingent liabilities stood at Rs 6,321 Mn as of 31 March 2024, including income tax dispute.
Related-Party Transaction
1 occurrenceRecent (last 12 months)
The company has related party transactions, with purchases from related parties accounting for 3.4% of total purchases and sales to related parties accounting for 6.9% of total sales.
Statutory dues in dispute
2 occurrencesRecent (last 12 months)
The company has disputed income tax dues for the years 2008-09, 2017-18, 2018-19, and 2020-21, with amounts disputed totaling INR 200 million and INR 100 million paid under protest.
Earlier (1-3 years ago)
The company has disputed statutory dues under the Income Tax Act, Service Tax, and Goods and Service Tax Act, with amounts disputed totaling INR 1,172 million, INR 1 million, and INR 8 million respectively, and disputes pending before various authorities.
Management & Board Governance
1 occurrenceEarlier (1-3 years ago)
Jonathan Hunt resigned as Managing Director & CEO effective February 10, 2025. Sibaji Biswas resigned as Chief Financial Officer and Executive Director effective November 30, 2024.